Favorable Japan Environment Nurtures Daiichi/CTL Cell Therapy Deal

Daiichi Sankyo's recent deal for Japan rights to a cell therapy agent illustrates the ongoing corporate appetite for assets able to benefit from the country's favorable regulatory framework for such products.

Daiichi Sankyo Co. Ltd.'s move to jump-start its pipeline in the regenerative medicine area by acquiring rights in Japan to a novel cell therapy continues a trend for pharma majors in the country to enter a field characterized by a highly supportive domestic regulatory environment.

The Japanese firm has licensed in Cell Therapy Ltd.'s (CTL) Heartcel, an allogeneic regenerative medicine comprising proprietary immuno-modulatory progenitor...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Focus On Asia

More from Scrip